SK Biopharmaceutical Acquires Majority Stake in US Proteobant
On the 14th, SK Biopharmaceuticals announced that it had acquired a 60% stake in Proteobant, USA on August 11th. The acquisition involved 40 million shares. SK Biopharmaceuticals had previously stated its goal of securing global targeted protein degradation (TPD) technology. Yuhan Corporation reported its performance for the first half of the year on the 14th. […]
Latest Business Updates: Syntekabio Converts 200,000 Shares, Hanmi Pharm Acquires 569 Shares, Medpacto Reports Operating Loss in Q2
Syntekabio Announces Conversion of Shares and Listing Date Syntekabio announced on August 10th that it will exercise its right to convert a total of 201,655 shares on August 9th and 10th. This conversion accounts for 1.35% of the total number of outstanding shares. The company’s stock will be listed on August 23rd. Kim Tae-yoon Acquires […]
Stock Options Granted by Bridge Bio and Other Companies Announce Dividends and Meeting Resolutions
Bridge Bio Announces Stock Option Grant and Issuance of New Shares Bridge Bio, a leading biotechnology company, has recently announced its decision to grant stock options for 15,000 ordinary shares. The stock options will be priced at 5,900 earned per share and will be valid from August 7, 2025, to August 6, 2030. The company […]
SK Biopharmaceuticals, 2Q deficit decreased… Possible turnaround in 4Q [NH투자증권]
[사진=SK바이오팜] NH Investment & Securities estimated on the 10th that the deficit of SK Biopharmaceuticals would decrease in the second quarter of this year. We maintain our Buy rating and target price of 105,000 won, respectively. NH Investment & Securities predicted that SK Biopharmaceuticals’ second-quarter sales would increase by 55% year-on-year to 82.7 billion won, […]
SK Biopharmaceuticals Acquires ProteoVant Sciences to Expand Pipeline and Secure Global TPD Technology
SK Biopharmaceuticals to Acquire ProteoVant Sciences for Global Expansion SK Biopharmaceuticals, under the leadership of CEO Lee Dong-hoon, has announced its decision to acquire a 60.0% stake in ProteoVant Sciences, a joint venture between Roivant Sciences and SK Corporation. With a projected investment of approximately 62 billion won, this acquisition marks a significant move towards […]
SK Biopharmaceuticals Acquires Proteobant to Secure Targeted Proteolytic Therapy Technology
SK Biopharmaceuticals Acquires Proteobant to Secure TPD Technology In a move to secure targeted proteolytic therapy (TPD) technology, SK Biopharmaceuticals has announced the acquisition of Proteobant. The South Korean company revealed that it would be acquiring a 60% stake in ProteoVant Sciences, a prominent US biotech firm, for approximately 62 billion won. By 2021, SK […]
SK Biopharmaceuticals ‘Cenobamate’ approved for marketing in Canada
[메디칼업저버 손형민 기자] An innovative new drug for epilepsy developed by SK Biopharmaceuticals (CEO Lee Dong-hoon), ‘Cenobamate’ (local product name: Xcofree) has been approved for sale in Canada. SK Biopharmaceuticals announced on the 14th that Health Canada has issued a Notice of Compliance for cenobamad and approved its application for marketing approval in Canada. Paladin […]
